福森药业(01652)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01652 福森药业

已收盘 08-14 13:29:16

1.040

-0.040

-3.70%

最高1.080	最低0.980	成交量6.60万
今开1.080	昨收1.080	日振幅9.26%
总市值7.69亿	流通市值7.69亿	总股本7.39亿
成交额6.73万	换手率0.01%	流通股本7.39亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01652","market":"HK","secType":"STK","nameCN":"福森药业","latestPrice":1.04,"timestamp":1786685356451,"preClose":1.08,"halted":0,"volume":66000,"delay":0,"changeRate":-0.03703703703703707,"floatShares":739000000,"shares":739000000,"eps":-0.0159,"marketStatus":"已收盘","change":-0.04,"latestTime":"08-14 13:29:16","open":1.08,"high":1.08,"low":0.98,"amount":67265,"amplitude":0.092593,"askPrice":1.05,"askSize":4000,"bidPrice":0.98,"bidSize":10000,"shortable":0,"etf":0,"ttmEps":-0.017737,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":5,"adr":0,"listingDate":1531238400000,"exchange":"SEHK","adjPreClose":1.08,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":1.987952,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01652","defaultTab":"news","newsList":[{"id":"1152326020","title":"福森药业7月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1152326020","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152326020?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:45","pubTimestamp":1785757545,"startTime":"0","endTime":"0","summary":"福森药业有限公司于2026年8月3日发布截至2026年7月31日的股份变动月报表。公告显示，公司法定股本总额仍保持在2,000万港元，普通股面值每股0.01港元，注册股本总额为2,000,000,000股，与上月相比未发生变动。当月公司确认维持了足够的公众持股量要求，股本总体保持稳定。公司在月报中确认，其所有股份变动及库房股份管理均符合香港联交所《上市规则》及相关法律法规要求。本次公告由公司秘书杨育康签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189552643","title":"福森药业（01652）四款产品拟中标全国第十二批药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=1189552643","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189552643?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:52","pubTimestamp":1785750763,"startTime":"0","endTime":"0","summary":"2026年8月3日，福森药业有限公司（01652）发布自愿公告称，在2026年7月31日举行的中国第十二批全国药品集中采购招标中，公司共有四个产品拟中标。这四款产品为：  \n1. 尼卡地平注射液（2ml：2mg，5ml：5mg）  \n2. 美阿沙坦钾片（40mg，80mg）  \n3. 复合磷酸氢钾注射液（5ml：磷酸二氢钾1.12g和磷酸氢二钾〔按K2HPO4计〕1.18g）  \n4. 地屈孕酮片（10mg）\n公告称，本次披露旨在让股东及潜在投资者了解公司最新业务进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656279463","title":"福森药业(01652)：四个产品拟中标全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656279463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656279463?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:48","pubTimestamp":1785750518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福森药业(01652)发布公告，在2026年7月31日的中国第十二批全国药品集中采购招标中，公司四个产品拟中标：尼卡地平注射液(2ml：2mg，5ml：5mg)、美阿沙坦钾片(40mg，80mg)、复合磷酸氢钾注射液(5ml：磷酸二氢钾1.12g和磷酸氢二钾(按K2HPO4计)1.18g)、地屈孕酮片(10mg)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475316.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189289550","title":"福森药业（01652）将河南福森药业增资款支付期限延至2026年10月8日","url":"https://stock-news.laohu8.com/highlight/detail?id=1189289550","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189289550?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:01","pubTimestamp":1785409273,"startTime":"0","endTime":"0","summary":"福森药业有限公司（01652）7月30日公告称，公司与投资者、南阳衡盛、Wealth Depot (HK)及目标公司就此前签署的增资协议订立补充协议，同意将增资价款的支付日期由原定的2026年8月7日延长至2026年10月8日或之前。除付款期限调整外，增资协议其他条款及条件维持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129269326","title":"福森药业（01652）首款激光打孔缓控释新药「甲磺酸多沙唑嗪缓释片」获中国NMPA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1129269326","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129269326?lang=zh_cn&edition=full","pubTime":"2026-07-10 20:12","pubTimestamp":1783685554,"startTime":"0","endTime":"0","summary":"2026年7月10日，福森药业有限公司公告称，其全资子公司河南福森药业有限公司研发的「甲磺酸多沙唑嗪缓释片」已获国家药品监督管理局批准上市，用于高血压及良性前列腺增生对症治疗。该产品系公司首个采用激光打孔技术制备的缓控释新药，上市后将进一步丰富福森药业的产品线，为良性前列腺增生和高血压患者提供更多治疗选择。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650818709","title":"福森药业(01652)：“甲磺酸多沙唑嗪缓释片”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2650818709","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650818709?lang=zh_cn&edition=full","pubTime":"2026-07-10 20:11","pubTimestamp":1783685497,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福森药业 发布公告，公司全资附属公司河南福森药业有限公司研发的“甲磺酸多沙唑嗪缓释片”，上市申请已获得中国国家药品监督管理局批准，批准用于高血压及良性前列腺增生对症治疗。“甲磺酸多沙唑嗪缓释片”目前已成为国内外治疗轻中度高血压的一线药物，也是治疗良性前列腺增生合并下尿路症状的一线用药。甲磺酸多沙唑嗪是选择性α1受体抑制剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01652","IPOS","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188158943","title":"福森药业（01652）特别股东大会高票通过向河南福森药业增资3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188158943","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188158943?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:53","pubTimestamp":1783587186,"startTime":"0","endTime":"0","summary":"财联社讯 2026年7月9日，福森药业有限公司 公布，于当日在香港举行的股东特别大会上，股东以投票表决方式通过全部普通决议案。该决议主要涉及同意投资者向河南福森药业有限公司增资人民币3亿元。增资协议签署日期为2026年6月18日。公告同时披露，香港中央证券登记有限公司被委任为点票监票员；全体董事均出席了本次股东特别大会。根据上市规则，因超过50%的投票权赞成，上述增资议案获正式通过。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123266704","title":"福森药业2026年6月无新增发行及回购，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1123266704","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123266704?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:16","pubTimestamp":1782987387,"startTime":"0","endTime":"0","summary":"福森药业于2026年7月2日发布2026年6月股份变动月报表，报告期为截至2026年6月30日。报告显示，福森药业注册股本维持在2,000,000,000股普通股，每股面值为港币0.01元，总额为港币20,000,000，与上个月底相同。当月在已发行股份数量、库藏股余额方面未出现增减变动。公告称，公司于2018年6月14日批准并在2019年7月19日采纳的购股权计划下，行使期为2019年10月19日至2028年6月13日，每股期权行使价为港币3.098元。据悉，本次公告由公司秘书杨育康于2026年7月2日签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646335791","title":"福森药业：帕拉米韦注射液获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2646335791","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646335791?lang=zh_cn&edition=full","pubTime":"2026-06-26 12:21","pubTimestamp":1782447674,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["01652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188529566","title":"福森药业帕拉米韦注射液获中国批准 为首款静脉用神经氨酸酶抑制剂流感治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1188529566","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188529566?lang=zh_cn&edition=full","pubTime":"2026-06-26 12:08","pubTimestamp":1782446895,"startTime":"0","endTime":"0","summary":"福森药业研发的帕拉米韦注射液已获得中国监管部门批准，用于静脉注射治疗流感。该药物成为国内首个获批的神经氨酸酶抑制剂类静脉用流感治疗药物。\n神经氨酸酶抑制剂是治疗流感的关键药物类别，此前国内已有口服和吸入剂型获批。帕拉米韦注射液的上市，为无法接受口服或吸入给药的重症流感患者提供了重要的静脉治疗选择。\n此次获批标志着福森药业在抗流感药物领域取得了重要进展，有望满足临床未竟的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645007547","title":"福森药业子公司引入国资股东，去年公司净利润续亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2645007547","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645007547?lang=zh_cn&edition=full","pubTime":"2026-06-23 11:56","pubTimestamp":1782187018,"startTime":"0","endTime":"0","summary":"6月23日早上，福森药业港交所公告称，公司于6月18日与投资者南阳产投健康产业集团有限公司、河南淅胜产业发展有限责任公司，以及公司全资附属公司南阳衡盛企业管理服务有限公司、WealthDepot(HK)、河南福森药业有限公司（简称河南福森或目标公司）订立增资协议，投资者将以合计人民币3亿元现金，认购河南福森新增注册资本，占增资后目标公司经扩大注册资本约34%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606233779509980.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606233779509980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160166971","title":"福森药业(01652)7月9日召开股东特别大会 审议向子公司增资3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160166971","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160166971?lang=zh_cn&edition=full","pubTime":"2026-06-23 06:25","pubTimestamp":1782167131,"startTime":"0","endTime":"0","summary":"关键信息：福森药业公告称，公司拟于2026年7月9日（星期四）14:00在香港皇后大道中99号中环中心59楼5906–5912室举行股东特别大会，审议重大增资事项。公司股份过户登记将于7月6日至9日暂停办理。投资者将合计出资人民币3亿元认购目标公司——河南福森药业有限公司新增注册资本。股东须于7月3日16:30前完成股份过户并于7月7日14:00前递交代理委任表格方可有效投票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644086142","title":"福森药业(01652)：河南福森获增资3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644086142","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644086142?lang=zh_cn&edition=full","pubTime":"2026-06-18 21:10","pubTimestamp":1781788237,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福森药业 发布公告，于2026年6月18日，投资者、南阳衡盛、Wealth Depot 及目标公司河南福森订立增资协议，投资者应以现金出资合共人民币3亿元，以认购目标公司新增注册资本，占增资后目标公司经扩大注册资本总额约34% 。董事会认为增资符合本公司及其股东整体利益。注资为河南福森引入额外资金，使其能够偿还若干债务并加强其营运资金状况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643355637","title":"福森药业：吡拉西坦注射液获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2643355637","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643355637?lang=zh_cn&edition=full","pubTime":"2026-06-16 12:08","pubTimestamp":1781582880,"startTime":"0","endTime":"0","summary":"南财智讯6月16日电，福森药业（01652.HK）发布自愿公告，公司全资附属公司嘉亨(珠海横琴)医药科技有限公司研发的“吡拉西坦注射液”上市申请已获中国国家药品监督管理局批准，适应症为急慢性脑血管病、脑外伤、中毒性脑病所致记忆减退及轻中度脑功能障碍，以及儿童智能发育迟缓。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606163772823974.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606163772823974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01652","IPOS","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184894276","title":"福森药业旗下吡拉西坦注射液获准用于记忆障碍及脑功能不全","url":"https://stock-news.laohu8.com/highlight/detail?id=1184894276","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184894276?lang=zh_cn&edition=full","pubTime":"2026-06-16 12:05","pubTimestamp":1781582712,"startTime":"0","endTime":"0","summary":"福森药业宣布，其生产的吡拉西坦注射液已获得批准，可用于治疗记忆障碍及相关脑功能不全症状。该药品的获批为公司产品线增添了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187935424","title":"福森药业2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1187935424","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187935424?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:11","pubTimestamp":1780312312,"startTime":"0","endTime":"0","summary":"福森药业有限公司于2026年6月1日披露了2026年5月股份变动月报表。报告期为2026年5月1日至2026年5月31日。公司法定/注册股本在本月未发生变动，依然为2,000,000,000股，每股面值为0.01港元，总额维持在20,000,000港元。报告期内，公司普通股的已发行股份数量为739,301,000股，与上月保持一致。库存股份数量在本月也无变动，结存为0股，公司确认达到了最低公共持股量的规定。上述事项已获公司董事会正式授权并符合相关规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634402500","title":"福森药业(01652.HK)：“注射用氯诺昔康”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2634402500","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634402500?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:29","pubTimestamp":1778491795,"startTime":"0","endTime":"0","summary":"格隆汇5月11日丨福森药业发布公告，集团的全资附属公司嘉亨医药科技有限公司研发的“注射用氯诺昔康”，上市申请已获得中国国家药品监督管理局批准，批准用于手术后急性中度疼痛的短期治疗。氯诺昔康系噻嗪类衍生物，是具有较强的镇痛和抗炎作用的非甾体类药物。作为一种镇痛药，氯诺昔康引起阿片类药物的呼吸抑制、成瘾性等风险较低，其术后镇痛效果与吗啡相当，但恶心、呕吐等不良反应更少。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/11172957063810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IPOS","BK1191","01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108330485","title":"福森药业4月股份变动月报表发布，股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1108330485","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108330485?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:16","pubTimestamp":1777893379,"startTime":"0","endTime":"0","summary":"福森药业于2026年5月4日发布截至2026年4月30日的股份变动月报表。公告显示，公司法定注册股本及已发行股份在报告期内均保持不变。报告期内，公司已发行股份数量为739,301,000股，与上月持平，未发生新增发行、回购或注销，库藏股数量亦始终为0股。此外，公司披露，于2018年6月14日授出并于2019年7月19日采纳的一项购股权计划保持不变。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185169815","title":"福森药业拟回购不超过10%已发行股本","url":"https://stock-news.laohu8.com/highlight/detail?id=1185169815","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185169815?lang=zh_cn&edition=full","pubTime":"2026-04-30 12:11","pubTimestamp":1777522311,"startTime":"0","endTime":"0","summary":"福森药业董事会宣布，计划向股东大会提呈一般及无条件授权，用于回购不超过公司已发行股本总数10%的股份。该议案将于2026年5月29日召开的股东周年大会审议。公告显示，截至最后可行日期，公司已发行股份总数约为739,301,000股。公司表示，此次回购将依据开曼群岛公司法及香港联交所相关上市规则进行。公司并宣布将于2026年5月26日至5月29日期间暂停办理股份过户。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福森药业拟回购不超过10%已发行股本","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146414881","title":"福森药业2025年收入下滑，年内亏损大幅收窄并加速拓展中草药业务","url":"https://stock-news.laohu8.com/highlight/detail?id=1146414881","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146414881?lang=zh_cn&edition=full","pubTime":"2026-04-30 12:11","pubTimestamp":1777522302,"startTime":"0","endTime":"0","summary":"福森药业是一家注册于开曼群岛的医药企业，于2018年7月在香港联合交易所有限公司主板上市，总部位于中国河南省浚川縣城区工业园区，并在香港设有营业地点。公司以中成药及相关产品的生产和销售为核心，近年陆续在全国范围内建立销售网络，并于2025年9月完成新一轮业务整合，获得约7,200万元银行资金支持，用于后续投资及运营。近年来公司收益自2021年的3.86亿元逐年下滑至2025年的2.73亿元，但亏损幅度在本期有所收窄。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"福森药业2025年收入下滑，年内亏损大幅收窄并加速拓展中草药业务","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01652"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fusenyy.com","stockEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":0.0385},{"period":"3month","weight":0.0385},{"period":"6month","weight":0.1613},{"period":"1year","weight":2.0423},{"period":"ytd","weight":0.35}],"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0434},{"period":"3month","weight":-0.0218},{"period":"6month","weight":-0.0441},{"period":"1year","weight":-0.0085},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"褔森药业有限公司是一家主要从事药材种植、药品研发生产、销售业务的公司。该公司的主营业务是销售双黄连口服液、双黄连注射液及其他药品。该公司还从事研发生产及销售多种以治疗感冒及发热、心血管疾病及贫血的中成药及西药药品。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.125,"avgChangeRate":-0.041654},{"month":2,"riseRate":0.375,"avgChangeRate":-0.018809},{"month":3,"riseRate":0.375,"avgChangeRate":-0.021269},{"month":4,"riseRate":0.375,"avgChangeRate":0.009302},{"month":5,"riseRate":0.25,"avgChangeRate":0.0099},{"month":6,"riseRate":0.125,"avgChangeRate":-0.04458},{"month":7,"riseRate":0.625,"avgChangeRate":-0.007535},{"month":8,"riseRate":0.666667,"avgChangeRate":0.122004},{"month":9,"riseRate":0.5,"avgChangeRate":0.132622},{"month":10,"riseRate":0.75,"avgChangeRate":0.062597},{"month":11,"riseRate":0.375,"avgChangeRate":-0.01734},{"month":12,"riseRate":0.5,"avgChangeRate":-0.037723}],"exchange":"SEHK","name":"福森药业","nameEN":"FUSEN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福森药业(01652)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福森药业(01652)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福森药业,01652,福森药业股票,福森药业股票老虎,福森药业股票老虎国际,福森药业行情,福森药业股票行情,福森药业股价,福森药业股市,福森药业股票价格,福森药业股票交易,福森药业股票购买,福森药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福森药业(01652)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福森药业(01652)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}